Figure 5.
Incidence of hot flushes and fatigue associated with combination therapy comprising LHRH-R agonists and antagonists with NHAs. Incidence is rounded to whole numbers. *The study reported only the incidence of treatment-related adverse events. LHRH-R, luteinizing hormone-releasing hormone receptor; NHAs, next-generation hormonal agents (i.e., abiraterone or enzalutamide).